HyperglycemiaNCT05447806
Diabetes Clinical Decision Support
A study testing Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support in people with Hyperglycemia and Hyperglycemia Stress, run by Milton S. Hershey Medical Center at 2 sites in United States.
Trial summary
The purpose of this study is to determine the impact of an electronic medical record clinical decision support tool on rates of dysglycemia in the hospital, and its clinical and economical outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hyperglycemia, Hyperglycemia Stress, Diabetes
- What is being tested?
- Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15,732 participants
- Where
- 2 sitesUnited States
- Study dates
- 15 Jul 2022to 16 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hospitalized adult (>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center
- Ambulatory adult (>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center
- Trigger of an alert or a disease management message
Who cannot join
- Children (<18 years)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Penn State Hershey Medical Center
Hershey, Pennsylvania, 17033
Ariana Pichardo-Lowden, MD, 717-531-0003 ext. 281452, apichardolowden@pennstatehealth.psu.edu
- Recruiting
Penn State Health St. Joseph Medical Center
Reading, Pennsylvania, 19605
Franciss Quigley, MD, 610 378 2440, fquigley@pennstatehealth.psu.edu
About this study
Official title: Glucose Management Clinical Decision Support to Improve Outcomes in Academic and Community Hospitals
The purpose of this study is to determine the impact of an electronic medical record clinical decision support tool on rates of dysglycemia in the hospital, and its clinical and economical outcomes. The study also evaluates the perspectives of providers regarding the tool's usefulness on disease management support, knowledge, and practice performance.
Read the detailed description
Approximately 9 million patients with diabetes (DM) are hospitalized annually and over 30% of inpatients without DM experience high glucose (HG) due to their acute illness. HG increases the risk of infectious and non- infectious complications and death, hospital length of stay (LOS), utilization of hospital resources and overall healthcare costs. While glucose control reduces these risks, controlling HG in the hospital is difficult due to multiple barriers such as recognizing and proactively treating glucose abnormalities, and adequately ordering insulin to treat HG in the hospital. Clinical decision support (CDS) is a system that uses computerized person- specific data in the electronic medical record (EMR) proven to improve hospital care. Among the various modalities, alert-CDS is shown to improve care delivery, providers' proactivity, and glucose control specifically in intensive care settings of academic institutions. However, alert-CDS has not yet been studied outside of intensive care units (ICU), or in community hospitals where most patients receive care. Furthermore, its impact on patients' outcomes has not been tested in any setting. The proposed project uses an innovative alert-CDS tool the investigators developed and validated which automatically identifies dysglycemia and inadequacies in insulin administration in the hospital. It alerts clinicians with recommendations to support decision making without superseding their clinical judgement. In the pilot study, it was found that this alert-CDS tool reduced recurrent high glucose levels and shortened LOS. Based on this promising preliminary data, in this project the investigators propose to study the impact of our CDS tool on clinical, economic and providers' performance outcomes among non-intensive care patients both in academic and community hospitals. This resource will be available intermittently in the EMR every 3 months for 36 months, thus allowing the comparison of 18 months of intervention and 18 months of standard care. Based on the pilot study, a sample size of 12,560 subjects will give an 80% power of detecting 0.34 days (~ 8 hours) difference in length of stay, the primary endpoint of our study. The investigators propose the following aims: Aim 1) To determine the impact of the alert-CDS over conventional care on the clinical outcomes of non-ICU patients in an academic and four community hospitals. Aim 2) To determine the impact of the alert-CDS over conventional care on the economic outcomes of non-ICU patients in an academic and four community hospital. Aim 3) To determine the impact of alert-CDS for inpatient glycemic control on providers' perspectives, competencies and practice performance between an academic and four community hospital. The study received an IRB waiver of consent for the inclusion of subjects identified in the electronic health record. The consent of clinicians participating in study surveys is implied by agreeing to respond to surveys. It is hypothesized that the tool will increase providers' knowledge and decision making to manage dysglycemia allowing them to make better decisions about insulin administration. It is also hypothesized that clinical and economic outcomes will be better during the time alert-CDS is available. The anticipated success of our study builds upon a well-established multidisciplinary team of investigators strongly supported by leadership stakeholders in hospitals within a health system. The proposed study has the potential of establishing a new paradigm in the management of dysglycemia in hospitalized patients with a major positive impact on clinical and economic outcomes.
- Conditions
- Hyperglycemia, Hyperglycemia Stress, Diabetes, PreDiabetes, Hypoglycemia
- Being tested
- Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support
- Keywords
- Clinical Decision Support, Electronic Medical Records, Health Systems Science, Hospital Management
- Medical subject headings
- Hyperglycemia, Diabetes Mellitus, Prediabetic State, Hypoglycemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active Electronic Medical Record Inpatient Diabetes Clinical Decision SupportDevice
This prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing.
| Study group | Role | What they receive |
|---|---|---|
| Active Inpatient Diabetes Clinical Decision Support | Experimental | The Active arm consists of participants treated during the "ON" phase of the GlucAlert-CDS tool. The tool operates through an automated process of rules embedded in the EMR recognizing hypoglycemia (established or impending); recurrent hyperglycemia (in type 1 and 2 DM, or stress hyperglycemia-SH); and inappropriate insulin use (sliding scales monotherapy if recurrent hyperglycemia in type 2 DM or SH, or any time in type 1 DM). If the tool's criteria are met, an alert in the EMR will notify the provider with the clinically recommended treatment. Receives: Device: Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support |
| Inactive Inpatient Diabetes Clinical Decision Support | No intervention | The Inactive arm consists of participants treated during the "OFF" phase of the GlucAlert-CDS Tool. Alerts will not be sent to provider's |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average hospital length of stay (LOS)
Number of days in the hospital
Measured: Duration of hospital admission, up to 3 months
Secondary outcomes (20)
Proportion of gap in care events
Number of events recognized for: 1) Hyperglycemia: recurrent hyperglycemia [>= 180/dl at least twice] or severe hyperglycemia [>= 250 mg/dl at least once] 2) Hypoglycemia: established hypoglycemia [<= 70 mg/dl] or impending hypoglycemia [71-80 mg/dl] 3)Inappropriate insulin use: among type 2 diabetes and stress hyperglycemia patients [sliding scale monotherapy when recurrent hyperglycemia present] or among type 1 diabetes [sliding scale monotherapy any time].
Measured: Duration of hospital admission, up to 3 months
Glycemic control parameters - Glucose metrics
Average glucose per admission, glucose range (Glucose value in mg/dl)
Measured: Duration of hospital admission, up to 3 months
Glycemic control parameters - average glucose per day per admission
Number of glucose values within the following categories: severe hypoglycemia (<= 40 mg/dl), moderate hypoglycemia (41-70 mg/dl), within normal limits but not desired (71-110 mg/dl), within target/less commonly recommended (111-140 mg/dl), within target (141-180 mg/dl), mild hyperglycemia (181-220 mg/dl), moderate hyperglycemia (221-300 mg/dl), severe hyperglycemia (>=301 mg/dl).
Measured: Duration of hospital admission, up to 3 months
Glycemic control parameters - glycemic variability
Standard deviation
Measured: Duration of hospital admission, up to 3 months
Incidence of inpatient mortality
Number of deceased patients
Measured: Duration of hospital admission, up to 3 months
Incidence of post-discharge mortality
Number of deceased patients
Measured: Up to 3 months after discharge
Proportion of hospital-acquired infections
Number of infections: 1)Hospital acquired pneumonia (HAP) 2)Catheter-associated urinary tract infections (CAUTI) 3)Clostridium difficile colitis 4)MRSA infections 5)Central Line associated Bloodstream Infection (CLABSI) 6)Bacteremia 7)Vancomycin Resistant Enterococcus 8)Skin and soft tissue infection (SSI) 9)Ventilator Acquired Pneumonia
Measured: Duration of hospital admission, up to 3 months
Proportion of surgical complications
Number of complications: 1)Wound dehiscence 2)Seroma 3)Surgical site infection 4)Acute organ rejection 5)Ventral/Ruptured Hernia 6)Ileus
Measured: Duration of hospital admission, up to 3 months
Proportion of medical complications
Number of complications: 1) Systemic inflammatory response syndrome SIRS 2)Sepsis 3)Severe sepsis 4)Septic shock 5)Decubitus ulcers 6)Deep venous thromboembolism 7)Pulmonary embolism 8)Diabetes ketoacidosis (DKA) 9)Hypoglycemia 10)Delirium 11)Encephalopathy 12)Mental status changes/altered mental status 13)Acute respiratory failure 14)Acute kidney injury/failure 15)Acute coronary syndrome/acute MI 16)Heart failure exacerbation 17)Stroke 18)Ventilatory support 19)Seizures 20)Coma 21)Irreversible neurologic injury 22)QT prolongation 23)Ventricular arrhythmias 24)Atrial arrhythmias 25)Sudden cardiac death 26)3)Fall occurred during hospitalization.
Measured: Duration of hospital admission, up to 3 months
Proportion of safety events
Number of events: 1)Diabetes Ketoacidosis diagnosis in type 1 diabetes after sliding scale insulin monotherapy gap in care event notification 2)Severe hypoglycemia (glucose level <= 40 mg/dl) after any hypoglycemia or hyperglycemia gap in care event notification 3)Hyperosmolar hyperglycemia state in type 2 diabetes after sliding scale insulin monotherapy gap in care event notification
Measured: Duration of hospital admission, up to 3 months
Frequency of severity of illness
Number of cases during hospitalization: Diagnosis Related Group (DRG) SOI categories 1, 2, 3, and 4.
Measured: Duration of hospital admission, up to 3 months
Proportion of diabetes medication optimization at the transition of care
Number of participants: Patients with A1c > 8% having their diabetes treatment adjusted upon discharge, defined as a preadmission diabetes treatment changed to include additional medications (insulin, oral or non-insulin injectable agents).
Measured: Duration of hospital admission, up to 3 months
Average reduction of glycohemoglobin level within 12 months of discharge
Percent level reduction: Glycohemoglobin reduction in relation to level prior to admission among patients who continue to follow with the health system
Measured: up to 12 months after being discharged from the hospital
Frequency of hospital readmission
Number of admissions: Admission within 7, 14, and 30 days from discharge.
Measured: Up to 30 days after being discharged from the hospital
Frequency of Intensive Care unit (ICU) transfers
Number of transfers: Refers to admission to ICU transferred from non-ICU units
Measured: Duration of hospital admission, up to 3 months
Cost of hospitalization
Log-transformed amount of hospital submitted claims
Measured: Duration of hospital admission, up to 3 months
Frequency of post-hospitalization skilled care needed from home to more advanced care
Number of discharges higher than preadmission level of care: defined as discharge to more advanced care than previous to admission such as a) Inpatient advanced care facilities, b) rehabilitation, c) nursing home care.
Measured: Duration of hospital admission, up to 3 months
Frequency of post-hospitalization skilled care needed
Number of discharges higher than preadmission level of care: defined as discharge to more advanced care than previous to admission such as a) Inpatient advanced care facilities, b) rehabilitation, c) nursing home care.
Measured: Duration of hospital admission, up to 3 months
Frequency of utilization of consulting services resource
Number of consults to diabetes services (endocrinology, diabetes education, hospitalists).
Measured: Duration of hospital admission, up to 3 months
Hospital revenue
Number in category of DRG for expected reimbursement
Measured: Duration of hospital admission, up to 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2022
- Study start15 Jul 2022
- Primary completion16 Oct 2025
- Study completion16 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HyperglycemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This prospective quasi-experiment will use an interrupted time series analysis to determine the impact of our novel glucose management CDS tool on the care of adult hospitalized patients outside of intensive care units in an academic and four community hospitals. The tool will be intermittently active in the EMR hospital-wide every 3 months for 36-months to enable an intervention (active) and a control (inactive) group of 18 months each in each hospital.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 15,732 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Milton S. Hershey Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Responsible party
- Principal investigator, Ariana Pichardo-Lowden, Milton S. Hershey Medical Center
- Investigators
- Ariana Pichardo-Lowden, MD, Principal investigator, Penn State College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05447806
- Sponsor's protocol ID
- STUDY00012931/20607
- Other IDs
- 1R01DK130992-01
- Status last verified
- Aug 2025
- First submitted
- 15 Jun 2022
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: This trial was granted prior to 2023
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Glucose Management Clinical Decision Support to Improve Outcomes in Academic and Community Hospitals
- ClinicalTrials.gov ID
- NCT05447806
- Acronym / sponsor ID
- STUDY00012931/20607
- Conditions
- Hyperglycemia, Hyperglycemia Stress, Diabetes, PreDiabetes, Hypoglycemia
- Keywords
- Clinical Decision Support, Electronic Medical Records, Health Systems Science, Hospital Management
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 15,732 participants (estimated)
- Lead sponsor
- Milton S. Hershey Medical CenterUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 15 Jul 2022 (actual)
- Primary completion
- 16 Oct 2025 (actual)
- Study completion
- 16 Oct 2026 (estimated)
- First posted
- 7 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the impact of an electronic medical record clinical decision support tool on rates of dysglycemia in the hospital, and its clinical and economical outcomes. The study also evaluates the perspectives of providers regarding the tool's usefulness on disease management support, knowledge, and practice performance.
Detailed description
Approximately 9 million patients with diabetes (DM) are hospitalized annually and over 30% of inpatients without DM experience high glucose (HG) due to their acute illness. HG increases the risk of infectious and non- infectious complications and death, hospital length of stay (LOS), utilization of hospital resources and overall healthcare costs. While glucose control reduces these risks, controlling HG in the hospital is difficult due to multiple barriers such as recognizing and proactively treating glucose abnormalities, and adequately ordering insulin to treat HG in the hospital. Clinical decision support (CDS) is a system that uses computerized person- specific data in the electronic medical record (EMR) proven to improve hospital care. Among the various modalities, alert-CDS is shown to improve care delivery, providers' proactivity, and glucose control specifically in intensive care settings of academic institutions. However, alert-CDS has not yet been studied outside of intensive care units (ICU), or in community hospitals where most patients receive care. Furthermore, its impact on patients' outcomes has not been tested in any setting. The proposed project uses an innovative alert-CDS tool the investigators developed and validated which automatically identifies dysglycemia and inadequacies in insulin administration in the hospital. It alerts clinicians with recommendations to support decision making without superseding their clinical judgement. In the pilot study, it was found that this alert-CDS tool reduced recurrent high glucose levels and shortened LOS. Based on this promising preliminary data, in this project the investigators propose to study the impact of our CDS tool on clinical, economic and providers' performance outcomes among non-intensive care patients both in academic and community hospitals. This resource will be available intermittently in the EMR every 3 months for 36 months, thus allowing the comparison of 18 months of intervention and 18 months of standard care. Based on the pilot study, a sample size of 12,560 subjects will give an 80% power of detecting 0.34 days (~ 8 hours) difference in length of stay, the primary endpoint of our study. The investigators propose the following aims: Aim 1) To determine the impact of the alert-CDS over conventional care on the clinical outcomes of non-ICU patients in an academic and four community hospitals. Aim 2) To determine the impact of the alert-CDS over conventional care on the economic outcomes of non-ICU patients in an academic and four community hospital. Aim 3) To determine the impact of alert-CDS for inpatient glycemic control on providers' perspectives, competencies and practice performance between an academic and four community hospital. The study received an IRB waiver of consent for the inclusion of subjects identified in the electronic health record. The consent of clinicians participating in study surveys is implied by agreeing to respond to surveys. It is hypothesized that the tool will increase providers' knowledge and decision making to manage dysglycemia allowing them to make better decisions about insulin administration. It is also hypothesized that clinical and economic outcomes will be better during the time alert-CDS is available. The anticipated success of our study builds upon a well-established multidisciplinary team of investigators strongly supported by leadership stakeholders in hospitals within a health system. The proposed study has the potential of establishing a new paradigm in the management of dysglycemia in hospitalized patients with a major positive impact on clinical and economic outcomes.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- This prospective quasi-experiment will use an interrupted time series analysis to determine the impact of our novel glucose management CDS tool on the care of adult hospitalized patients outside of intensive care units in an academic and four community hospitals. The tool will be intermittently active in the EMR hospital-wide every 3 months for 36-months to enable an intervention (active) and a control (inactive) group of 18 months each in each hospital.
| Arm | Type | Receives |
|---|---|---|
| Active Inpatient Diabetes Clinical Decision Support | Experimental | Device: Active Electronic Medical Record Inpatient Diabetes Clinical Decision SupportThe Active arm consists of participants treated during the "ON" phase of the GlucAlert-CDS tool. The tool operates through an automated process of rules embedded in the EMR recognizing hypoglycemia (established or impending); recurrent hyperglycemia (in type 1 and 2 DM, or stress hyperglycemia-SH); and inappropriate insulin use (sliding scales monotherapy if recurrent hyperglycemia in type 2 DM or SH, or any time in type 1 DM). If the tool's criteria are met, an alert in the EMR will notify the provider with the clinically recommended treatment. |
| Inactive Inpatient Diabetes Clinical Decision Support | No intervention | –The Inactive arm consists of participants treated during the "OFF" phase of the GlucAlert-CDS Tool. Alerts will not be sent to provider's |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Hospitalized adult (>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center
- Ambulatory adult (>18 years) patients at Penn State Health, Hershey Medical Center, St. Joseph's Hospital, Hampden Medical Center, Holy Spirit Medical Center, and Lancaster Medical Center
- Trigger of an alert or a disease management message
Key exclusion criteria (1 listed)
- Children (<18 years)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active Electronic Medical Record Inpatient Diabetes Clinical Decision SupportThis prospective intervention will be carried out over 36 months and encompass 12 alternating GlucAlert-CDS phases lasting 3 months each. Six active phases (ON period) and six inactive phases (OFF period) will represent 18 months of intervention and control respectively. GlucAlert-CDS recognizes gaps in care denoting the automatic process of subjects' identification and inclusion. During the ON period, gap in care events detected in patients' EMR will evoke alert messages and care recommendations for clinicians in real time for their consideration. These notifications are programmed to be delivered to primary inpatient providers in direct care of these hospitalized patients. During the OFF period, the program will record the gaps in care events detected, but alerts will be inactive for providers' viewing. | Device | Active Inpatient Diabetes Clinical Decision Support |
Primary outcome
Average hospital length of stay (LOS)
Time frame: Duration of hospital admission, up to 3 months
Number of days in the hospital
20 secondary outcomes
Proportion of gap in care events
Time frame: Duration of hospital admission, up to 3 months
Glycemic control parameters - Glucose metrics
Time frame: Duration of hospital admission, up to 3 months
Glycemic control parameters - average glucose per day per admission
Time frame: Duration of hospital admission, up to 3 months
Glycemic control parameters - glycemic variability
Time frame: Duration of hospital admission, up to 3 months
Incidence of inpatient mortality
Time frame: Duration of hospital admission, up to 3 months
Incidence of post-discharge mortality
Time frame: Up to 3 months after discharge
Proportion of hospital-acquired infections
Time frame: Duration of hospital admission, up to 3 months
Proportion of surgical complications
Time frame: Duration of hospital admission, up to 3 months
Proportion of medical complications
Time frame: Duration of hospital admission, up to 3 months
Proportion of safety events
Time frame: Duration of hospital admission, up to 3 months
Frequency of severity of illness
Time frame: Duration of hospital admission, up to 3 months
Proportion of diabetes medication optimization at the transition of care
Time frame: Duration of hospital admission, up to 3 months
Average reduction of glycohemoglobin level within 12 months of discharge
Time frame: up to 12 months after being discharged from the hospital
Frequency of hospital readmission
Time frame: Up to 30 days after being discharged from the hospital
Frequency of Intensive Care unit (ICU) transfers
Time frame: Duration of hospital admission, up to 3 months
Cost of hospitalization
Time frame: Duration of hospital admission, up to 3 months
Frequency of post-hospitalization skilled care needed from home to more advanced care
Time frame: Duration of hospital admission, up to 3 months
Frequency of post-hospitalization skilled care needed
Time frame: Duration of hospital admission, up to 3 months
Frequency of utilization of consulting services resource
Time frame: Duration of hospital admission, up to 3 months
Hospital revenue
Time frame: Duration of hospital admission, up to 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Individual participant dataSharing planned: No. This trial was granted prior to 2023
Related trials for Hyperglycemia
Not yet recruitingEarly Phase 1
Efficacy of the pA1c®HI Postbiotic in Metabolic Regulation in Healthy Individuals With Hyperglycemia
Hyperglycemias, Prediabetes
Not yet recruiting
Effects of Mango on Insulin Sensitivity in Prediabetes
Pre Diabetes
Not yet recruitingObservational study
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
Obesity, Diabetes
Active, not recruiting
Insulin Balanced Infusion System
Hyperglycemia, Diabetes
Not yet recruitingObservational study
Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
End Stage Kidney Disease (ESKD), Hyperglycaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ariana Pichardo-Lowden, MD principal investigator
Penn State College of Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active Electronic Medical Record Inpatient Diabetes Clinical Decision Support in people with Hyperglycemia and Hyperglycemia Stress, run by Milton S. Hershey Medical Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ariana Pichardo-Lowden, MD (7175310003 ext. 281452, apichardolowden@pennstatehealth.psu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average hospital length of stay (LOS) (time frame: Duration of hospital admission, up to 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.